Serotonin (5-hydroxytryptamine, 5-HT) is a monoamine neurotransmitter and peripheral signaling molecule synthesized exclusively from the essential amino acid tryptophan. Its biosynthesis, storage, release, and reuptake constitute the molecular machinery that virtually every clinically used serotonergic drug targets, directly or indirectly. Understanding this machinery at the mechanistic level is the prerequisite for understanding why SSRIs work, why their onset is delayed, why serotonin syndrome occurs, and why peripheral and central serotonin pools behave as pharmacologically distinct systems.
Serotonin biosynthesis proceeds in two enzymatic steps. The first and rate-limiting step is the hydroxylation of L-tryptophan to 5-hydroxytryptophan (5-HTP) by the enzyme tryptophan hydroxylase (TPH). Two genetically and anatomically distinct isoforms of TPH exist: TPH1 and TPH2. TPH1 is expressed predominantly in peripheral tissues, most abundantly in the enterochromaffin (EC) cells of the gastrointestinal mucosa and in pinealocytes of the pineal gland. TPH2 is expressed exclusively in neurons, including the raphe nuclei of the brainstem, which are the primary source of central nervous system (CNS) serotonin. This isoform distinction has direct clinical relevance: telotristat ethyl, a TPH1 inhibitor approved for carcinoid syndrome-associated diarrhea, acts peripherally without crossing the blood-brain barrier (BBB) and therefore reduces gut serotonin synthesis without affecting CNS serotonin levels.1 The second biosynthetic step is the decarboxylation of 5-HTP to serotonin by aromatic L-amino acid decarboxylase (AADC, also called DOPA decarboxylase), a pyridoxal phosphate-dependent enzyme expressed in both peripheral and CNS tissues. AADC is not rate-limiting under normal conditions because 5-HTP is efficiently decarboxylated as it is produced.
The rate-limiting nature of the TPH step has important physiological consequences. TPH activity is regulated by substrate availability, meaning that the plasma concentration of free tryptophan (the fraction not bound to albumin and therefore available for transport across the BBB via the large neutral amino acid transporter) influences CNS serotonin synthesis. This is the mechanistic basis for the observation that carbohydrate intake, by stimulating insulin release, promotes uptake of branched-chain amino acids into muscle and increases the ratio of tryptophan to competing amino acids at the BBB transporter, thereby increasing brain tryptophan availability and serotonin synthesis. Conversely, diets high in other large neutral amino acids, or conditions reducing albumin-bound tryptophan release (as in liver disease), can reduce CNS serotonin synthesis. TPH2 activity in raphe neurons is also regulated by neuronal firing rate and by feedback from autoreceptors, establishing a homeostatic loop between serotonergic neuronal activity and the rate of new serotonin synthesis.2
Newly synthesized serotonin in both peripheral EC cells and raphe neurons is packaged into secretory vesicles by vesicular monoamine transporters (VMATs). Peripheral EC cells and platelets use VMAT1, while CNS neurons use VMAT2. Both isoforms use the proton electrochemical gradient across the vesicular membrane to drive serotonin uptake into vesicles against its concentration gradient, concentrating serotonin to millimolar levels within the vesicle. VMAT2 is also the target of tetrabenazine and valbenazine, drugs used to treat hyperkinetic movement disorders, which deplete monoamine stores including serotonin, dopamine, and norepinephrine by blocking vesicular packaging. Following an action potential, calcium influx triggers vesicle fusion with the plasma membrane and exocytotic release of serotonin into the synaptic cleft (in neurons) or into the lamina propria and portal circulation (in EC cells). The magnitude of the serotonin signal is determined by the number of vesicles released, which is a function of firing frequency and calcium concentration at the release site.3
Reuptake of released serotonin is mediated primarily by the serotonin transporter (SERT, gene symbol SLC6A4), a sodium- and chloride-dependent secondary active transporter belonging to the solute carrier 6 (SLC6) family. SERT is expressed on presynaptic serotonergic neurons in the CNS and on the apical membrane of intestinal EC cells and platelets in the periphery. In the CNS, SERT reuptake is the dominant mechanism terminating synaptic serotonin action; extracellular serotonin is also subject to diffusion out of the synaptic cleft and to enzymatic degradation, but reuptake accounts for the majority of clearance. SERT transports one serotonin molecule per transport cycle together with one sodium ion and one chloride ion, driven by the electrochemical gradient for sodium. The transporter is the primary molecular target of SSRIs (selective serotonin reuptake inhibitors) and is also blocked, to varying degrees, by SNRIs (serotonin-norepinephrine reuptake inhibitors), TCAs (tricyclic antidepressants), and several other psychotropic drugs.4 SERT occupancy of 80% or greater by an SSRI is generally required for clinically meaningful antidepressant effect, a threshold that is reached at standard therapeutic doses for most agents in the class.
The tryptophan hydroxylase (TPH) step is rate-limiting for serotonin synthesis, making TPH the logical target for drugs that need to reduce peripheral serotonin production without central effects. Telotristat ethyl selectively inhibits TPH1 in EC cells, reducing serotonin synthesis at the source in carcinoid syndrome. Because it does not cross the blood-brain barrier (BBB), central serotonin levels are unaffected. This isoform selectivity is the pharmacological principle that makes targeted peripheral serotonin reduction possible without neuropsychiatric consequences.
Serotonin that is not taken back up into the presynaptic terminal by SERT, or that escapes reuptake in peripheral tissues, undergoes enzymatic catabolism. The dominant catabolic pathway produces 5-hydroxyindoleacetic acid (5-HIAA), a metabolite excreted in urine that serves as the principal biochemical marker for excess serotonin production in clinical practice. Understanding this pathway is necessary for interpreting 5-HIAA measurements, predicting drug interactions involving MAO inhibitors, and understanding the mechanism of serotonin toxicity.
The first step in serotonin catabolism is oxidative deamination by monoamine oxidase (MAO), a flavoenzyme located on the outer mitochondrial membrane of neurons, intestinal epithelium, liver, and other tissues. Two isoforms of MAO exist with distinct substrate preferences and tissue distributions. MAO-A has higher affinity for serotonin and norepinephrine and is the dominant isoform for serotonin catabolism in both the CNS and the peripheral gut. MAO-B preferentially oxidizes phenylethylamine and benzylamine and has lower affinity for serotonin at physiological concentrations, though it contributes to serotonin catabolism when MAO-A is inhibited or overwhelmed. This isoform specificity explains why selective MAO-B inhibitors such as selegiline, used in Parkinson disease, carry a lower risk of hypertensive crisis from tyramine interactions than non-selective or MAO-A-selective inhibitors, because MAO-A in the gut wall is the primary barrier against tyramine absorption. MAO-A oxidizes serotonin to 5-hydroxyindoleacetaldehyde, with the release of ammonia and hydrogen peroxide as byproducts. The hydrogen peroxide generated in this step contributes to oxidative stress in tissues with high monoamine turnover, which has been implicated in the pathophysiology of mitochondrial dysfunction associated with excessive MAO activity.5
The aldehyde intermediate 5-hydroxyindoleacetaldehyde is highly reactive and is rapidly converted to 5-HIAA by aldehyde dehydrogenase (ALDH), primarily the mitochondrial isoform ALDH2. 5-HIAA is water-soluble and excreted in urine, making it measurable in 24-hour urine collections. Under normal conditions in adults, 24-hour urinary 5-HIAA excretion ranges from approximately 2 to 9 mg per day, reflecting baseline serotonin turnover primarily from gut EC cells. In patients with serotonin-secreting carcinoid tumors, urinary 5-HIAA is typically markedly elevated, often exceeding 30–50 mg per day in symptomatic carcinoid syndrome. A 24-hour urine 5-HIAA measurement has a sensitivity of approximately 70–75% and specificity of approximately 90% for carcinoid syndrome, with higher values seen in midgut carcinoids, which produce more serotonin than hindgut or bronchial carcinoids.6 False positive elevations of urinary 5-HIAA occur with dietary intake of serotonin-rich foods including walnuts, bananas, pineapple, avocado, and tomatoes, and with several drugs including acetaminophen, caffeine, and fluorouracil, necessitating dietary restrictions and medication review before collection.
Pharmacological inhibition of MAO-A, whether by irreversible agents such as phenelzine and tranylcypromine or by the reversible MAO-A inhibitor (RIMA) moclobemide, profoundly alters serotonin catabolism. When MAO-A is inhibited, serotonin that escapes SERT reuptake accumulates in the synaptic cleft and in the cytoplasm of serotonergic neurons, since re-packaged serotonin that leaks from vesicles can no longer be degraded by mitochondrial MAO. The combination of MAO-A inhibition with any drug or agent that increases synaptic serotonin release or blocks SERT reuptake creates the conditions for serotonin syndrome: excess serotonin accumulates beyond the capacity of postsynaptic receptor desensitization to compensate, leading to simultaneous overstimulation of multiple 5-HT receptor subtypes. The severity of this interaction is greatest with irreversible MAO-A inhibitors because MAO activity cannot recover until new enzyme is synthesized, a process requiring approximately 2 weeks after drug discontinuation.7 This is the mechanistic basis for the mandatory 14-day washout period required between stopping an irreversible MAOI and starting any serotonergic drug, and the 5-week washout required after stopping fluoxetine before starting an MAOI, due to the long half-life of its active metabolite norfluoxetine.
A 24-hour urinary 5-hydroxyindoleacetic acid (5-HIAA) level above 25 mg per day is strongly suggestive of a serotonin-secreting carcinoid tumor and warrants imaging. However, several factors confound interpretation. Dietary sources of serotonin (walnuts, bananas, pineapple, avocado, tomatoes, plums) must be restricted for 48 hours before and during the collection. Drugs that falsely elevate 5-HIAA include acetaminophen and fluorouracil; drugs that falsely lower it include aspirin, corticotropin (ACTH), and heparin. In patients on monoamine oxidase inhibitors (MAOIs), serotonin catabolism is impaired and 5-HIAA will be low even in the presence of excess serotonin production. Spot urine 5-HIAA-to-creatinine ratios can be used when 24-hour collection is impractical but are less reliable.
A minor alternative catabolic pathway converts serotonin to 5-hydroxytryptophol via alcohol dehydrogenase acting on the aldehyde intermediate, rather than aldehyde dehydrogenase converting it to 5-HIAA. This pathway is quantitatively minor under normal circumstances but becomes more prominent when aldehyde dehydrogenase activity is impaired, such as during significant ethanol consumption (ethanol competes for ALDH2) or with disulfiram use. The diversion of the serotonin aldehyde toward the alcohol rather than the acid metabolite can produce spuriously low 5-HIAA measurements in patients who consume alcohol in the period preceding urine collection, another preanalytical variable that must be accounted for in clinical interpretation.15
Serotonin acts on one of the most pharmacologically diverse receptor families in biology. With seven receptor families (5-HT1 through 5-HT7) encompassing at least 14 distinct subtypes, serotonin produces excitatory or inhibitory effects depending entirely on which receptor subtype is expressed at a given location. The clinician who understands this receptor landscape can predict the effects of drugs that activate, block, or modulate these receptors, and can anticipate the pattern of toxicity when serotonergic excess occurs at multiple receptor types simultaneously.
The 5-HT1 receptor family comprises five subtypes (5-HT1A, 5-HT1B, 5-HT1D, 5-HT1E, and 5-HT1F), all of which are negatively coupled to adenylyl cyclase via Gi/Go proteins. Activation of 5-HT1 receptors generally produces inhibitory effects: reduction of cyclic AMP (cAMP) production, opening of potassium channels leading to membrane hyperpolarization, and closure of voltage-gated calcium channels reducing neurotransmitter release. The 5-HT1A subtype is expressed at high density in the dorsal raphe nucleus, where it functions as a somatodendritic autoreceptor regulating the firing rate of serotonergic neurons, and in limbic areas including the hippocampus and amygdala, where it modulates mood and anxiety. Buspirone and related azapirones act as partial agonists at 5-HT1A, producing anxiolytic effects through this limbic mechanism.
In the context of SSRI pharmacotherapy, the 5-HT1A autoreceptor plays a pivotal role in the therapeutic lag: acute SERT blockade increases synaptic serotonin, but simultaneous activation of presynaptic 5-HT1A autoreceptors reduces raphe neuron firing, limiting serotonin release and attenuating the net increase in serotonergic transmission. Only after chronic SSRI exposure do these autoreceptors desensitize, allowing sustained increased serotonergic output. The 5-HT1B and 5-HT1D subtypes function as both presynaptic autoreceptors on axon terminals (regulating serotonin release) and as postsynaptic heteroreceptors; they are the principal targets of the triptan class of antimigraine drugs, which act as agonists at these subtypes to produce cranial vasoconstriction and inhibit trigeminal nociceptive signaling.8
The 5-HT2 receptor family includes three subtypes (5-HT2A, 5-HT2B, and 5-HT2C), all coupled to Gq proteins and signaling through phospholipase C activation, inositol trisphosphate (IP3) generation, and intracellular calcium release. Unlike the inhibitory 5-HT1 family, 5-HT2 receptor activation is generally excitatory. The 5-HT2A subtype is widely expressed in the cerebral cortex (particularly on pyramidal neurons of layer V), limbic system, and vascular smooth muscle. Cortical 5-HT2A activation is the primary mechanism through which classical psychedelics, including lysergic acid diethylamide (LSD), psilocin (the active metabolite of psilocybin), and mescaline, produce their perceptual and cognitive effects. Second-generation antipsychotics such as clozapine, olanzapine, and quetiapine are potent 5-HT2A antagonists, and this property contributes to their more favorable extrapyramidal side effect profile compared to first-generation agents. Excess 5-HT2A stimulation during serotonin syndrome produces the characteristic neuromuscular features of the syndrome, including clonus, hyperreflexia, and tremor.
The 5-HT2B subtype is expressed in the heart (particularly valvular interstitial cells), gut, and lung; chronic 5-HT2B agonism by agents such as ergotamine, fenfluramine, and the now-withdrawn weight loss agent dexfenfluramine causes cardiac valvulopathy through proliferation of valvular interstitial cells, the mechanism underlying fenfluramine-associated valvular heart disease. The 5-HT2C subtype is expressed predominantly in the central nervous system (CNS), including the choroid plexus, basal ganglia, and limbic areas, and influences appetite regulation, energy homeostasis, and dopaminergic neurotransmission; several atypical antipsychotics with 5-HT2C antagonism are associated with weight gain through disinhibition of appetite circuits.9
The 5-HT3 receptor is unique within the serotonin receptor family as the only ionotropic receptor: it is a ligand-gated ion channel forming a pentameric structure homologous to the nicotinic acetylcholine receptor superfamily. Activation of the 5-HT3 receptor opens a nonselective cation channel permeable to sodium, potassium, and calcium, producing rapid membrane depolarization. 5-HT3 receptors are highly expressed on vagal afferent neurons in the gut and in the chemoreceptor trigger zone (CTZ) of the area postrema in the brainstem, where they mediate the emetic response to chemotherapy, radiation, and post-operative stimuli. The 5-HT3 antagonist class, including ondansetron, granisetron, and palonosetron, blocks these receptors to produce antiemetic effects, representing one of the most clinically significant serotonin receptor pharmacology applications outside of psychiatry. 5-HT3 receptors also modulate pain transmission in the spinal cord and contribute to visceral nociception in the gut, making them relevant to the pathophysiology and treatment of irritable bowel syndrome (IBS).10
The 5-HT4 receptor is coupled to Gs proteins and stimulates adenylyl cyclase, increasing cAMP production and activating protein kinase A. In the gastrointestinal tract, 5-HT4 receptors are expressed on enteric neurons of the submucosal and myenteric plexuses, where their activation accelerates gastrointestinal transit and promotes intestinal secretion by stimulating the ascending excitatory limb of the peristaltic reflex. This makes 5-HT4 agonism the mechanistic target for GI prokinetic agents including metoclopramide (which also has D2 antagonist activity) and the more selective agent prucalopride (approved for chronic constipation in adults). In the CNS, 5-HT4 receptors are expressed in the hippocampus and basal ganglia and have been investigated as targets for cognitive enhancement. The 5-HT5, 5-HT6, and 5-HT7 receptors are less extensively characterized clinically but are increasingly recognized as pharmacologically relevant. The 5-HT6 receptor, expressed in the striatum and cortex, is a Gs-coupled receptor targeted by several antipsychotics as an off-target mechanism contributing to cognitive effects. The 5-HT7 receptor, also Gs-coupled, is expressed in the thalamus, hypothalamus, and limbic areas; it modulates circadian rhythm, sleep, and thermoregulation, and its blockade contributes to the antidepressant and sleep-normalizing profile of several multimodal agents including vortioxetine and lurasidone.1114
5-HT1 (A, B, D, E, F): Gi-coupled; inhibitory; reduce cAMP. 5-HT1A: buspirone (partial agonist), SSRI autoreceptor desensitization target. 5-HT1B/D: triptan agonism for migraine.
5-HT2 (A, B, C): Gq-coupled; excitatory; increase IP3 and intracellular calcium. 5-HT2A: target of classic psychedelics (agonists) and atypical antipsychotics (antagonists); mediates neuromuscular features of serotonin syndrome. 5-HT2B: cardiac valvulopathy with chronic agonism (ergotamine, fenfluramine). 5-HT2C: appetite regulation; antagonism contributes to antipsychotic-associated weight gain.
5-HT3: Ionotropic (ligand-gated cation channel); rapid depolarization. Vagal afferents and CTZ; target of ondansetron, granisetron, palonosetron. Mediates chemotherapy-induced emesis and visceral nociception.
5-HT4: Gs-coupled; increase cAMP. GI prokinesis; target of metoclopramide and prucalopride.
5-HT6 and 5-HT7: Gs-coupled; emerging targets. 5-HT7 blockade contributes to antidepressant and circadian effects of vortioxetine and lurasidone.
One of the most clinically consequential features of serotonin pharmacology is the strict anatomical separation between peripheral and central serotonin pools. Approximately 90% of the body's serotonin resides in the periphery, predominantly in enterochromaffin cells of the GI mucosa, with a smaller but significant fraction stored in platelets. The remaining 10% is synthesized within the CNS by raphe neurons and acts as a neurotransmitter. These two pools are functionally isolated by the blood-brain barrier, which is impermeable to serotonin itself, meaning that peripheral serotonin excess (as in carcinoid syndrome) does not directly cause the neuropsychiatric features of central serotonin excess, and drugs that raise central serotonin levels do not do so by increasing peripheral serotonin entry into the brain.
The blood-brain barrier (BBB) is formed by specialized cerebral capillary endothelial cells joined by tight junctions, supported by astrocytic end-feet and pericytes, that collectively restrict the paracellular and transcellular movement of molecules between blood and brain interstitium. Serotonin itself is a charged, hydrophilic molecule at physiological pH and does not cross the intact BBB by passive diffusion. Furthermore, no carrier-mediated transport system actively transports serotonin across the BBB; the tryptophan that serves as the precursor is transported (via the large neutral amino acid transporter, LAT1), but the amine product is not. This means that CNS serotonin levels are entirely dependent on de novo synthesis within raphe neurons from tryptophan delivered across the BBB, a critical distinction from peripheral pools supplied from dietary tryptophan hydroxylated in gut EC cells.12
The two-pool architecture creates a compartmentalization that is pharmacologically exploited in drug design. Drugs intended to modify central serotonin neurotransmission must themselves cross the BBB, generally requiring sufficient lipophilicity and molecular size below approximately 500 daltons to traverse the endothelial cell membranes. SSRIs and SNRIs are designed to cross the BBB and block SERT on central serotonergic nerve terminals. By contrast, telotristat ethyl is deliberately designed with physicochemical properties that prevent BBB penetration, allowing selective inhibition of TPH1 in peripheral EC cells without altering central serotonin synthesis. The 5-HT3 antagonists used as antiemetics (ondansetron, granisetron) act partly on peripheral vagal afferents in the gut and partly at the chemoreceptor trigger zone (CTZ) of the area postrema, a circumventricular organ that lies outside the BBB; their central antiemetic action does not require BBB penetration in the conventional sense. This anatomical nuance is relevant when interpreting why 5-HT3 antagonists suppress chemotherapy-induced vomiting without producing central serotonergic effects.13
The platelet serotonin pool is a pharmacologically significant component of the peripheral compartment. Platelets do not synthesize serotonin but absorb it from portal blood via SERT expressed on the platelet surface, concentrating serotonin in dense granules for release during platelet activation. Platelet serotonin release at sites of vascular injury contributes to vasoconstriction and to potentiation of platelet aggregation through 5-HT2A receptor activation on adjacent platelets. SSRIs, by blocking platelet SERT, progressively deplete platelet serotonin stores over days to weeks of treatment. The clinical consequence is impaired platelet serotonin-mediated amplification of aggregation, contributing to the increased bleeding risk associated with SSRI use, particularly when combined with NSAIDs, aspirin, or anticoagulants.4 This mechanism is distinct from antiplatelet drugs that block ADP or thromboxane pathways, and does not produce a platelet function abnormality detectable on standard coagulation tests.
Patients with carcinoid syndrome may have markedly elevated circulating serotonin levels, yet they do not develop the neuromuscular features (clonus, hyperreflexia, agitation) characteristic of serotonin syndrome. The explanation lies in the two-pool concept: circulating peripheral serotonin cannot cross the intact blood-brain barrier (BBB), so even extreme peripheral serotonin excess does not produce central 5-HT receptor overstimulation. The symptoms of carcinoid syndrome (flushing, diarrhea, bronchospasm, right heart disease) are entirely mediated by peripheral serotonin acting on vascular, enteric, and cardiac receptors. Serotonin syndrome, by contrast, requires excess serotonin within the CNS acting on central 5-HT1A and 5-HT2A receptors, and is produced exclusively by drugs that either increase central serotonin release or block SERT-mediated reuptake in the brain.
The two-pool concept also has implications for interpreting plasma serotonin measurements and urinary 5-HIAA levels in the clinical evaluation of serotonergic drug effects. Plasma serotonin concentrations reflect predominantly platelet serotonin content and peripheral pool activity; they do not correlate with central serotonergic tone and cannot be used to assess whether a patient is on an adequate antidepressant dose or at risk for serotonin syndrome from a centrally acting drug combination. Urinary 5-HIAA primarily reflects gut serotonin turnover from EC cells. Neither biomarker provides a window into central serotonin neurotransmission, which remains measurable only indirectly through CNS imaging techniques such as positron emission tomography (PET) with SERT-binding radioligands or through cerebrospinal fluid (CSF) 5-HIAA measurements in research settings.12
Peripheral serotonin is not a passive byproduct of central monoamine neurotransmission but a highly active signaling molecule with major roles in gastrointestinal physiology, hemostasis, and vascular tone regulation. The clinical importance of this peripheral biology extends to the mechanisms of GI side effects of serotonergic drugs, bleeding risk with SSRI use, vascular effects of triptans and ergotamines, and the multisystem manifestations of carcinoid syndrome.
In the gastrointestinal tract, serotonin functions as the primary initiator of the peristaltic reflex. Enterochromaffin (EC) cells, specialized neuroendocrine cells in the intestinal mucosa, detect luminal mechanical distension, chemical stimuli, and osmotic changes through mechanosensitive ion channels and chemosensory receptors on their luminal surface. In response to these stimuli, EC cells release serotonin basally into the lamina propria, where it acts on intrinsic primary afferent neurons (IPANs) of the submucosal plexus via 5-HT3 and 5-HT4 receptors. The activated IPANs initiate the peristaltic reflex by signaling ascending excitatory and descending inhibitory enteric motor neurons, producing coordinated muscle contraction oral to the bolus and relaxation caudal to it. The quantitative dominance of EC cells as the body's serotonin reservoir (approximately 90% of total body serotonin) reflects this fundamental role of serotonin as the gut's peristaltic trigger. Excess EC cell serotonin production in carcinoid syndrome produces the diarrhea characteristic of the syndrome through unrelenting peristaltic activation, and this is the target of both somatostatin analogs (which suppress EC cell secretion) and telotristat (which reduces EC cell serotonin synthesis).6
Platelet serotonin biology is intimately linked to hemostasis. Platelets circulate without serotonin but actively accumulate it from portal blood via SERT expressed on their surface membrane, loading it into dense granules (also called delta granules) alongside ADP, calcium, and other mediators. Platelet SERT uptake is so efficient that the portal and systemic venous serotonin concentrations are maintained at very low levels (approximately 0.5–1 nanomolar free plasma serotonin), with the majority of circulating serotonin bound within platelet dense granules. When platelets are activated at a site of vascular injury by collagen, thrombin, or ADP, they release their dense granule contents including serotonin. Released serotonin acts on 5-HT2A receptors on adjacent platelets, amplifying aggregation, and on 5-HT2A receptors on vascular smooth muscle, producing vasoconstriction at the injury site to reduce blood flow. This physiological role explains why SSRI-induced depletion of platelet serotonin stores impairs the serotonin-mediated amplification of the platelet response, increasing bleeding time and bleeding risk particularly in the context of surgical procedures or concurrent use of other antiplatelet or anticoagulant agents.4
The vascular effects of serotonin depend entirely on the receptor subtype engaged, the vascular bed, and the functional state of the endothelium. In vessels with intact endothelium, serotonin can produce vasodilation through 5-HT1 receptor-mediated stimulation of endothelial nitric oxide synthase (eNOS) and prostacyclin release. In vessels with damaged or absent endothelium, or in conditions of endothelial dysfunction, the vasoconstrictor effect of 5-HT2A receptor activation on vascular smooth muscle predominates. This duality is clinically significant: in coronary arteries with normal endothelium, serotonin produces mild vasodilation; in atherosclerotic coronary arteries with dysfunctional endothelium, serotonin produces vasoconstriction, which can contribute to vasospastic angina and Prinzmetal angina. Triptans, which act as 5-HT1B agonists producing cranial vasoconstriction, are contraindicated in patients with coronary artery disease precisely because 5-HT1B receptors are also expressed in coronary vasculature and triptan-induced coronary vasoconstriction could precipitate ischemia in susceptible patients.8
In the pulmonary circulation, serotonin is a potent vasoconstrictor and smooth muscle mitogen. The lungs normally extract and inactivate a substantial fraction of serotonin delivered in venous blood, both through the action of pulmonary endothelial SERT and through MAO-A present in pulmonary endothelial cells. In patients with carcinoid syndrome, the liver normally inactivates serotonin released from midgut carcinoid tumors via MAO-A in hepatocytes, protecting the systemic circulation; when hepatic metastases are present and serotonin bypasses hepatic clearance, or in the case of extra-abdominal (pulmonary or ovarian) carcinoid tumors, serotonin reaches the systemic circulation in elevated concentrations, producing the full carcinoid syndrome. Right heart valvular disease in carcinoid syndrome occurs because venous blood returning from the gut passes through the right heart before reaching the lungs; serotonin delivered directly to right heart valvular tissue acts as a mitogen via 5-HT2B receptors, stimulating valvular interstitial cell proliferation and producing tricuspid and pulmonary valvular plaques leading to regurgitation and stenosis. Left heart valves are protected by pulmonary MAO-A inactivation in most cases, explaining the predominantly right-sided valvular pathology.1
The kidneys express both SERT and MAO-A, contributing to peripheral serotonin clearance. Renal SERT in proximal tubular cells participates in the tubular secretion and reabsorption of serotonin, and urinary serotonin excretion is measurable but much less clinically useful than urinary 5-HIAA as a diagnostic marker. In chronic kidney disease, impaired renal clearance of serotonin and its metabolites can modestly elevate plasma serotonin levels, though this does not produce clinical serotonergic effects. Of greater clinical relevance is that several serotonergic drugs undergo renal excretion of active metabolites: desvenlafaxine is excreted largely unchanged in urine, and dose adjustment is required in severe renal impairment; venlafaxine and its active metabolite O-desmethylvenlafaxine also require dose adjustment in renal insufficiency. Paroxetine levels are increased in renal impairment due to reduced clearance, warranting lower starting doses.
Kulke MH, Hörsch D, Caplin ME, et al. Telotristat ethyl, a tryptophan hydroxylase inhibitor for the treatment of carcinoid syndrome. J Clin Oncol. 2017;35(1):14–23.
doi:10.1200/JCO.2016.69.2780Walther DJ, Bader M. A unique central tryptophan hydroxylase isoform. Biochem Pharmacol. 2003;66(9):1673–1680.
doi:10.1016/S0006-2952(03)00556-2Fon EA, Edwards RH. Molecular mechanisms of neurotransmitter release. Muscle Nerve. 2001;24(5):581–601.
doi:10.1002/mus.1044Andrade C, Sandarsh S, Chethan KB, Nagesh KS. Serotonin reuptake inhibitor antidepressants and abnormal bleeding: a review for clinicians and a reconsideration of mechanisms. J Clin Psychiatry. 2010;71(12):1565–1575.
doi:10.4088/JCP.09r05786bluShih JC, Chen K, Ridd MJ. Monoamine oxidase: from genes to behavior. Annu Rev Neurosci. 1999;22:197–217.
doi:10.1146/annurev.neuro.22.1.197Delle Fave G, Kwekkeboom DJ, Van Cutsem E, et al; Barcelona Consensus Conference Participants. ENETS Consensus Guidelines for the management of patients with gastroduodenal neoplasms. Neuroendocrinology. 2012;95(2):74–87.
doi:10.1159/000335595Isbister GK, Buckley NA, Whyte IM. Serotonin toxicity: a practical approach to diagnosis and treatment. Med J Aust. 2007;187(6):361–365.
doi:10.5694/j.1326-5377.2007.tb01282.xFerrari MD, Roon KI, Lipton RB, Goadsby PJ. Oral triptans (serotonin 5-HT1B/1D agonists) in acute migraine treatment: a meta-analysis of 53 trials. Lancet. 2001;358(9294):1668–1675.
doi:10.1016/S0140-6736(01)06711-3Berger M, Gray JA, Roth BL. The expanded biology of serotonin. Annu Rev Med. 2009;60:355–366.
doi:10.1146/annurev.med.60.042307.110802Gershon MD, Tack J. The serotonin signaling system: from basic understanding to drug development for functional GI disorders. Gastroenterology. 2007;132(1):397–414.
doi:10.1053/j.gastro.2006.11.002Hedlund PB. The 5-HT7 receptor and disorders of the nervous system: an overview. Psychopharmacology (Berl). 2009;206(3):345–354.
doi:10.1007/s00213-009-1626-0Stahl SM. Stahl's Essential Psychopharmacology: Neuroscientific Basis and Practical Applications. 4th ed. Cambridge, UK: Cambridge University Press; 2013:354–382.
Marty M, Pouillart P, Scholl S, et al. Comparison of the 5-hydroxytryptamine3 (serotonin) antagonist ondansetron (GR 38032F) with high-dose metoclopramide in the control of cisplatin-induced emesis. N Engl J Med. 1990;322(12):816–821.
doi:10.1056/NEJM199003223221205Roth BL, Hanizavareh SM, Blum AE. Serotonin receptors represent highly favorable molecular targets for cognitive enhancement in schizophrenia and other disorders. Psychopharmacology (Berl). 2004;174(1):17–24.
doi:10.1007/s00213-004-1794-0Svensson S, Some M, Lundsjo A, Helander A, Cronholm T, Hoog JO. Activities of human alcohol dehydrogenases in the metabolic pathways of ethanol and serotonin. Eur J Biochem. 1999;262(2):324–329.
doi:10.1046/j.1432-1327.1999.00351.x